Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paula Alejandra Blanco"'
Autor:
Mariana Aris, Alicia Inés Bravo, Heli Magalí Garcia Alvarez, Ibel Carri, Enrique Podaza, Paula Alejandra Blanco, Cecilia Rotondaro, Sofia Bentivegna, Morten Nielsen, María Marcela Barrio, José Mordoh
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
The CSF-470 cellular vaccine plus BCG and rhGM-CSF increased distant metastases-free survival in cutaneous melanoma patients stages IIB-IIC-III relative to medium dose IFN-α2b (CASVAC-0401 study). Patient-045 developed a mature vaccination site (VAC
Externí odkaz:
https://doaj.org/article/1b5a04c46d524798be7f46dc13775992
Autor:
Mariana Aris, Alicia Inés Bravo, María Betina Pampena, Paula Alejandra Blanco, Ibel Carri, Daniel Koile, Patricio Yankilevich, Estrella Mariel Levy, María Marcela Barrio, José Mordoh
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
The allogeneic therapeutic vaccine CSF-470 has demonstrated a significant benefit over medium-dose IFNα2b in the distant metastasis-free survival for stages IIB–IIC–III cutaneous melanoma patients in a randomized phase II/III clinical trial (CAS
Externí odkaz:
https://doaj.org/article/4d1040ed2d6845afb7bb57100dae5ff0
Autor:
José Mordoh, María Betina Pampena, Mariana Aris, Paula Alejandra Blanco, Mónica Lombardo, Erika María von Euw, Soledad Mac Keon, Michelle Yépez Crow, Alicia Inés Bravo, Juan Manuel O’Connor, Ana Gabriela Orlando, Franco Ramello, Estrella Mariel Levy, María Marcela Barrio
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB–III cutaneous me
Externí odkaz:
https://doaj.org/article/d4638689320b44b78fcc3f3ed3451f2d